Biologicals targeting type 2 immunity: Lessons learned from asthma, chronic urticaria and atopic dermatitis
- 12 August 2019
- journal article
- review article
- Published by Wiley in European Journal of Immunology
- Vol. 49 (9), 1334-1343
- https://doi.org/10.1002/eji.201948156
Abstract
During the last decades, progression of research has led to great achievements for treatment and therapy of several disabling disorders, particularly in the field of chronic inflammatory diseases. The increased knowledge of the molecular mechanisms operating in such diseases has represented the first step in this process, and the discovery of molecules able to interfere with the natural history of the diseases, has been the second. This review is focused on the effects of biologics on type 2 diseases such as asthma, chronic urticaria and atopic dermatitis, both biologics just approved for clinical application and also those that are currently undergoing clinical trials. We will also discuss aspects and emphasize clinical trials and recently published studies, as well as research that is currently in the progress, which will be highly relevant for basic immunologists. Likewise, we will cover aspects that are pertinent for clinical immunologists and highlight translational studies that are evaluating novel biologicals in animal models.Keywords
This publication has 57 references indexed in Scilit:
- Timing and duration of omalizumab response in patients with chronic idiopathic/spontaneous urticariaJournal of Allergy and Clinical Immunology, 2015
- The 3 major types of innate and adaptive cell-mediated effector immunityJournal of Allergy and Clinical Immunology, 2015
- Mepolizumab versus placebo for asthmaPublished by Wiley ,2014
- Mepolizumab Treatment in Patients with Severe Eosinophilic AsthmaThe New England Journal of Medicine, 2014
- Effects of an Anti-TSLP Antibody on Allergen-Induced Asthmatic ResponsesThe New England Journal of Medicine, 2014
- International ERS/ATS guidelines on definition, evaluation and treatment of severe asthmaEuropean Respiratory Journal, 2013
- T helper cells plasticity in inflammationCytometry Part A, 2013
- A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine–refractory chronic idiopathic urticariaJournal of Allergy and Clinical Immunology, 2011
- Mepolizumab for Prednisone-Dependent Asthma with Sputum EosinophiliaThe New England Journal of Medicine, 2009
- Thymic Stromal Lymphopoietin Expression Is Increased in Asthmatic Airways and Correlates with Expression of Th2-Attracting Chemokines and Disease SeverityThe Journal of Immunology, 2005